Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Investor Presentation (October 2018)
24 slides from Microbot Medical's investor presentation, Oct 1, 2018
Slide 1: Microbot Medical: Robotizing Endolumen Surgery
microbot medical ROBOTIZING ENDOLUMEN SURGERY NASDAQ:MBOT
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS icrobot THIS DOCUMENT IS PRIVATE AND CONFIDENTIAL, CONTAINS SENSITIVE BUSINESS INFORMATION OF MICROBOT MEDICAL INC. (“MICROBOT") AND IS NOT FOR PUBLIC DISTRIBUTION. This document has been prepared for informational purposes only and is provided personally to you. By accept
Slide 3: The Initial Spark...
THE INITIAL SPARK... microbot
Slide 4: Evolution of Surgery...
EVOLUTION OF SURGERY... microbot ..and the revolution of robotics in healthcare medical Biomedical micro-robotics ‘applications Tomorrow Micro-robotics Today Robot Assisted Surgery 1990-2000 Minimally Invasive Surgery 1980-1990 Freehand Surgery
Slide 5: Micro-Robotics Applications
MICRO-ROBOTICS APPLICATIONS microbot medical mvwo Drug Delivery Sensing ot Electrodes © Biomedical Occlusion micro-robotics applications Brachytherapy Hyperthermia a Bey xk Stem Cells Ablation Biopsy Scaffolding Annual review of BioMed, Micro-robots for MIS, 2010
Slide 6: The Medical Robotics Market
THE MEDICAL ROBOTICS MARKET microbot medical MIS Expected to Reach >$50B Market by 2019 Becoming Smaller, Automated, and More Precise
Slide 7: The Medical Robotics Market
microbot THE MEDICAL ROBOTICS MARKET medical
Slide 8: Our Mission
microbot medical OUR MISSION Enable all stakeholders to transform medical treatments and improve patient efficacy through our micro-invasive robotic platforms
Slide 9: Technology Platforms
TECHNOLOGY PLATFORMS microbot ViRob @ Autonomous Advancing Micro-Robot (AAMR) @ ViRob demonstrates the ability to advance within cavities similar to the typical human body's lumens TipCAT ® TipCAT is a disposable, flexible, self-propelled, see & treat endoscope/catheter CardioSert —————— _— @ Combin
Slide 10: ViRob First Product
VIROB FIRST PRODUCT ViRob ® Self Cleaning Shunt (SCS) @® Anovel shunt technology for the continuous prevention of shunt blockage in hydrocephalus and NPH patients
Slide 11: Slide 11
Slide 12: VP Shunt Market Opportunity
VP SHUNT MARKET OPPORTUNITY @ Hydrocephalus and Normal Pressure Hydrocephalus (NPH), are medical conditions in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain. ® Hydrocephalus occurs in about 1 in every 500 births in the U.S. alone’? @ Over 1,000,0
Slide 13: Current Shunt Failure
CURRENT SHUNT FAILURE viRob Approximately 50% of shunts in the pediatric population fail within two years of placement and repeated neurosurgical operations are often required! Ventricular catheter blockage is by far the most frequent event?
Slide 14: Self Cleaning Shunt (SCS) — Lab Study
SELF CLEANING SHUNT (SCS) — LAB STUDY SCS showed the ability to prevent blockage on a shunt opening AVERAGE BLOCKAGE ~70% Occlusion Free 50 20 10 0 SCS 2 ScsS3 scs4 Ctrl 1 Blockage percentage [%] fo) oO MSCS 2 mscs4 @SCS3 1 Control 1
Slide 15: Self Cleaning Shunt (SCS) — Lab Study
SELF CLEANING SHUNT (SCS) — LAB STUDY (@) Hydroc sicr Bristol 2 Laboratory Testing of Micro-Robotic Self-Cleaning Shunt UK Shunt Testing Lab, Cambridge University, UK CONCLUSIONS: “Microbot Medical SCS presents low hydrodynamic resistance. The SCS behaves as a standard ventricular catheter and does
Slide 16: Self Cleaning Shunt (SCS) — Pre Clinical
SELF CLEANING SHUNT (SCS) — PRE CLINICAL @ Wayne State University — Goal: Test and finalize the design of the Company's SCS, using Dr. Carolyn Harris’ bio-reactor system that mimics human brain tissue dynamics and biology. — Result: Supports the SCS’s potential as a viable technology for preventing
Slide 17: Initiation of Pivotal Study
INITIATION OF PIVOTAL STUDY @ Commenced pivotal study for SCS in September 2018 @ Includes a larger sample size compared to the initial study to validate positive outcome of initial study @ Primary and secondary endpoints will seek to validate the safety and efficacy of the SCS that will be activate
Slide 18: Organization & Infrastructure to Execute Plan
microbot medical ORGANIZATION & INFRASTRUCTURE TO EXECUTE PLAN
Slide 19: Robust IP Platform
ROBUST IP PLATFORM FAMILY US PATENT/APP NO. US 9,061,118 OTHER COUNTRIES Granted: EP (DE, FR, GB, IT), CA, TipCAT Tip Propelled Device for Motion Through a Passage US 9,937,326 Pace) US 15/936,876 inflatable Chamber Device for Motion Through a US 9,427,143 Passage US 15/218,025 ey) US 8,430,810 Infl
Slide 20: Proven Leadership Team
PROVEN LEADERSHIP TEAM microbot medical Prof. Moshe Shoham Member of the Scientific Advisory Board & Co-Founder Prof. Shoham is a worldwide acclaimed authority in the field of robotics, conducting research in the robotic field for over the past 20 years, with a special focus on kinematics and dynami
Slide 21: Proven Leadership Team
PROVEN LEADERSHIP TEAM microbot medical David Ben Naim CFO Mr. Ben Naim is a CPA licensed in the State of Israel. Prior to joining Microbot Medical, Mr. Ben Naim operated DBN Financial © Previously served as CFO of Insuline Medical Ltd, a public company listed on the Tel-Aviv Stock Exchange (TASE:IN
Slide 22: Strengthened Balance Sheet
STRENGTHENED BALANCE SHEET microbot The sale of STEM assets for $4 million Non-dilutive grants in excess of $735,000 Two separate capital market transactions totaling over $13.5 million Israel Ministry of Economy; European Commission
Slide 23: Multiple Opportunities
MULTIPLE OPPORTUNITIES micropot PLATFORMS, 7) = ~ co) Ez 4 si ee o =) 7) APPLICATIONS
Slide 24: Investment Considerations
INVESTMENT CONSIDERATIONS microbot Developing three micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs Potential pipeline designed to deliver additional solutions to other medical conditions every 12-24 months Proven leadership
Microbot Medical — Investor Presentation (October 2018) on 6ix